CN108815488B - Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof - Google Patents

Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof Download PDF

Info

Publication number
CN108815488B
CN108815488B CN201810907965.7A CN201810907965A CN108815488B CN 108815488 B CN108815488 B CN 108815488B CN 201810907965 A CN201810907965 A CN 201810907965A CN 108815488 B CN108815488 B CN 108815488B
Authority
CN
China
Prior art keywords
essential oil
preparation
parts
compound
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810907965.7A
Other languages
Chinese (zh)
Other versions
CN108815488A (en
Inventor
伍振峰
黄小英
杨明
陈冰玉
郑琴
王雅琪
万娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi University of Traditional Chinese Medicine
Original Assignee
Jiangxi University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi University of Traditional Chinese Medicine filed Critical Jiangxi University of Traditional Chinese Medicine
Priority to CN201810907965.7A priority Critical patent/CN108815488B/en
Publication of CN108815488A publication Critical patent/CN108815488A/en
Application granted granted Critical
Publication of CN108815488B publication Critical patent/CN108815488B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A61K36/8905—Cyperus (flatsedge)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a compound essential oil preparation for treating dysmenorrhea and a preparation method and a using method thereof, and relates to the technical field of essential oil preparations, wherein the essential oil composition preparation comprises the following components in parts by mass: 1-3 parts of angelica essential oil, 0.6-1.5 parts of ligusticum wallichii essential oil, 0.3-0.7 part of cortex moutan essential oil, 0.2-0.4 part of rhizoma cyperi essential oil, 0.25-0.8 part of folium artemisiae argyi essential oil, 0.4-1 part of lavender essential oil, 0.2-0.5 part of geranium essential oil, 0.2-0.5 part of basil essential oil and 0.1-0.4 part of ginger essential oil, and the essential oil composition has the technical problems that although the analgesic is taken for a long time to treat dysmenorrhea, symptoms can be relieved, but not radical treatment can be realized, and side reactions can be generated.

Description

Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof
Technical Field
The invention relates to the technical field of essential oil preparations, in particular to a compound essential oil preparation for treating dysmenorrhea and a preparation method and a using method thereof.
Background
Dysmenorrhea refers to pain before and after menstruation or during menstruation, manifested as lower abdominal pain, distention, soreness of waist, and other symptoms including headache, asthenia, dizziness, nausea, etc., and no organic lesions in pelvic cavity and genital tract. Dysmenorrhea is a common and high-incidence disease of women and frequently occurs in adolescent women, and according to survey, the female dysmenorrhea accounts for 33.19% in China, wherein the dysmenorrhea accounts for 75% in adolescence.
Along with the development of economy in China, dysmenorrhea is easily caused or aggravated by practical problems of high working and living double pressure of women and the like. The long-term and repeated onset of dysmenorrhea not only brings great physical and psychological pains to women, but also affects the normal life and work of patients due to severe pain.
At present, for the treatment of dysmenorrhea, modern medicine mainly adopts analgesic drugs such as oral prostaglandin synthetase inhibitors, non-steroidal hormone drugs, spasmolytic analgesic drugs, calcium magnesium preparations and the like for treatment, however, the analgesic drugs can relieve symptoms but cannot radically cure the symptoms, and the long-term dependence on the analgesic drugs can generate side reactions such as nausea, gastrointestinal mucosa ulcer, abdominal pain, granulocytopenia and the like, and the curative effect cannot be lasting, so that the traditional Chinese medicine is not suitable for long-term use.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a compound essential oil preparation for treating dysmenorrhea, which is used for relieving the technical problems that the symptoms can be relieved but not cured, side reactions can be generated, and the compound essential oil preparation is not suitable for long-term use when an analgesic is taken for a long time to treat the dysmenorrhea.
The compound essential oil preparation for treating dysmenorrhea provided by the invention comprises the following components in parts by mass: 1-3 parts of angelica essential oil, 0.6-1.5 parts of ligusticum wallichii essential oil, 0.3-0.7 part of cortex moutan essential oil, 0.2-0.4 part of rhizoma cyperi essential oil, 0.25-0.8 part of folium artemisiae argyi essential oil, 0.4-1 part of lavender essential oil, 0.2-0.5 part of geranium essential oil, 0.2-0.5 part of basil essential oil and 0.1-0.4 part of ginger essential oil.
Further, the compound essential oil preparation for treating dysmenorrhea comprises the following components in parts by mass: 1.5-2.5 parts of angelica essential oil, 0.7-1.2 parts of ligusticum wallichii essential oil, 0.4-0.6 part of cortex moutan essential oil, 0.25-0.4 part of rhizoma cyperi essential oil, 0.2-0.7 part of folium artemisiae argyi essential oil, 0.45-0.8 part of lavender essential oil, 0.3-0.4 part of geranium essential oil, 0.3-0.4 part of basil essential oil and 0.2-0.3 part of ginger essential oil.
Further, the compound essential oil preparation for treating dysmenorrhea comprises the following components in parts by mass: 2-2.5 parts of angelica essential oil, 0.7-1 part of ligusticum wallichii essential oil, 0.45-0.55 part of cortex moutan essential oil, 0.25-0.35 part of rhizoma cyperi essential oil, 0.2-0.5 part of folium artemisiae argyi essential oil, 0.45-0.7 part of lavender essential oil, 0.3-0.4 part of geranium essential oil, 0.3-0.4 part of basil essential oil and 0.2-0.3 part of ginger essential oil.
Further, the compound essential oil preparation for treating dysmenorrhea also comprises 90-98 parts of base oil, preferably 91.4-96.7 parts, and more preferably 92-96 parts by mass;
preferably, the base oil is selected from at least one of sweet almond oil, jojoba oil, grape seed oil or wheat germ oil, preferably jojoba oil.
Further, the essential oil of angelica, ligusticum wallichii, cortex moutan, cyperus rotundus, artemisia argyi, lavender, geranium, basil and ginger is extracted from angelica sinensis, ligusticum wallichii, cortex moutan, cyperus rotundus, artemisia argyi, lavender, geranium, basil and ginger by steam distillation.
Further, the compound essential oil preparation for treating dysmenorrhea also comprises pharmaceutically acceptable auxiliary materials;
preferably, the excipient comprises at least one of an excipient, a binder, a filler, a lubricant, an antioxidant, a preservative, or a thickener.
Furthermore, the compound essential oil preparation for treating dysmenorrhea is an external preparation;
preferably, the preparation is in the form of a patch, a cream, a microemulsion gel, a suspension or a microcapsule.
The invention also aims to provide a preparation method of the compound essential oil preparation for treating dysmenorrhea, which comprises the following steps: mixing radix Angelicae sinensis essential oil, rhizoma Ligustici Chuanxiong essential oil, cortex moutan essential oil, rhizoma Cyperi essential oil, folium Artemisiae Argyi essential oil, Lavender essential oil, flos Pelargonii Hortori essential oil, herba Ocimi essential oil and rhizoma Zingiberis recens essential oil with optional base oil uniformly to obtain compound essential oil preparation for treating dysmenorrhea.
Further, the preparation method of the compound essential oil preparation for treating dysmenorrhea comprises the following steps: sequentially adding radix Angelicae sinensis essential oil, rhizoma Ligustici Chuanxiong essential oil, cortex moutan essential oil, rhizoma Cyperi essential oil, folium Artemisiae Argyi essential oil, Lavender essential oil, flos Pelargonii Hortori essential oil, herba Ocimi essential oil and rhizoma Zingiberis recens essential oil into the base oil, and mixing well to obtain the compound essential oil preparation for treating dysmenorrhea.
The invention also aims to provide a using method of the compound essential oil preparation for treating dysmenorrhea, which comprises the following steps: applying the essential oil to the Guanyuan acupoint of the navel and the three-inch lower abdomen below the navel when female is dysmenorrhea or 3-7 days before menstrual period.
The fifth purpose of the invention is to provide a using method of the compound essential oil preparation for treating dysmenorrhea, which comprises the following steps: the compound essential oil preparation is applied to Guanyuan acupoint of three-inch lower abdomen below navel and navel when female is dysmenorrhea or 3-7 days before menstrual period.
The basil essential oil and the ginger essential oil are cooperatively matched, so that the basil essential oil and the ginger essential oil have strong fat solubility and permeability, are quickly absorbed by organisms, have the effects of pungent fragrance, qi regulation, blood circulation promotion and pain relief, have obvious pain relieving and menstruation regulating effects, can pass through an external medicine, are safe, efficient, simple, convenient and quick, and have higher patient acceptance and higher compliance.
The preparation method of the compound essential oil preparation for treating dysmenorrhea, provided by the invention, is simple in process and convenient to operate, and can be suitable for industrial mass production and improve the production efficiency.
The compound essential oil preparation for treating dysmenorrhea provided by the invention is used as an effective component, and the Chinese angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil, the lavender essential oil, the geranium essential oil, the basil essential oil and the ginger essential oil are cooperatively matched, so that the compound essential oil preparation has strong fat solubility and permeability, is quickly absorbed by an organism, has the effects of pungent fragrance flowing away, aromatic qi regulating, blood circulation promoting and pain relieving, has an obvious pain relieving and menstruation regulating effect, can be used for external use, is simple, convenient and quick, has higher patient acceptance and has stronger compliance.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
According to one aspect of the invention, the invention provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by weight: 1-3 parts of angelica essential oil, 0.6-1.5 parts of ligusticum wallichii essential oil, 0.3-0.7 part of cortex moutan essential oil, 0.2-0.4 part of rhizoma cyperi essential oil, 0.25-0.8 part of folium artemisiae argyi essential oil, 0.4-1 part of lavender essential oil, 0.2-0.5 part of geranium essential oil, 0.2-0.5 part of basil essential oil and 0.1-0.4 part of ginger essential oil.
Typical but not limiting parts by mass of the essential oil of angelica in the present invention are for example 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.71.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 or 3 parts.
The angelica essential oil has the functions of enriching blood and activating blood, regulating menstruation and relieving pain, and relaxing bowel, and is used for treating blood deficiency and chlorosis, dizziness and palpitation, irregular menstruation, amenorrhea and dysmenorrheal, deficiency cold and abdominal pain, constipation due to intestinal dryness, rheumatic arthralgia, carbuncle, cellulitis and pyocutaneous disease.
Typical but not limiting mass parts of the essential oil of ligusticum wallichii are 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45 or 1.5 parts.
The essential oil of rhizoma Ligustici Chuanxiong has effects of promoting blood circulation, activating qi-flowing, dispelling pathogenic wind and relieving pain. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, abdominal pain, and pricking pain in chest and hypochondrium.
Typical but not limiting mass parts of cortex moutan essential oil in the present invention are, for example, 0.3, 0.35, 0.38, 0.4, 0.42, 0.45, 0.48, 0.5, 0.52, 0.55, 0.58, 0.6, 0.62, 0.65, 0.68 or 0.7 parts.
The cortex moutan essential oil has the effects of clearing heat and cooling blood, and promoting blood circulation to remove blood stasis. Can be used for treating toxic heat, speckle, hematemesis, epistaxis, nocturnal fever, morning cool, anhidrosis, amenorrhea, dysmenorrhea, carbuncle, swelling, sore, traumatic injury, and pain.
Typical but not limiting parts by mass of the essential oil of cyperus rotundus in the present invention are for example 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39 or 0.4 parts.
The nutgrass galingale rhizome essential oil has the functions of promoting the circulation of qi, resolving depression, regulating menstruation and relieving pain. Can be used for treating stagnation of qi due to stagnation of liver-qi, chest pain, hypochondrium pain, abdominal distention and pain, dyspepsia, chest and abdominal distention and fullness, hernia due to cold, abdominal pain, breast pain, menoxenia, amenorrhea, and dysmenorrhea.
Typical but not limiting mass parts of the essential oil of artemisia argyi in the present invention are, for example, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75 or 0.8 parts.
The folium Artemisiae Argyi essential oil has effects of dispelling cold, relieving pain, warming channels and stopping bleeding.
Typical but not limiting parts by mass of the lavender essential oil in the present invention are for example 0.45, 0.48, 0.5, 0.52, 0.55, 0.58, 0.6, 0.62, 0.65, 0.68, 0.7, 0.72, 0.75, 0.78 or 0.8 parts.
The lavender essential oil has effects of relieving tension, calming heart, calming and calming, and also has spasmolytic effect on ileum and uterus smooth muscle.
Typical but non-limiting parts by mass of geranium essential oil in the present invention are for example 0.2, 0.22, 0.25, 0.28, 0.3, 0.32, 0.35, 0.38, 0.4, 0.42, 0.45, 0.48 or 0.5 parts.
The geranium essential oil can promote blood circulation, relieve pain, resist bacteria, improve premenstrual syndrome, strengthen circulation function and ensure smooth circulation.
Typical but not limiting mass parts of basil essential oil in the present invention are e.g. 0.2, 0.22, 0.25, 0.28, 0.3, 0.32, 0.35, 0.38, 0.4, 0.42, 0.45, 0.48 or 0.5 parts.
The basil essential oil is extracted from basil, can relieve pain and pain, greatly improve dysmenorrheal, treat gastroenteropathy, resist spasm and bacteria, effectively promote blood circulation, improve dysfunction, stabilize mood and resist depression.
Typical but not limiting parts by mass of the ginger essential oil in the present invention are for example 0.1, 0.12, 0.15, 0.18, 0.2, 0.22, 0.25, 0.28, 0.3, 0.32, 0.35, 0.38 or 0.4 parts.
The ginger essential oil can eliminate accumulated blood clots, is helpful for improving the state of excess moisture and body fluid in a body, and can diminish inflammation and relieve itching.
In the invention, the reason for preparing the medicament for treating dysmenorrhea by using the essential oil as the raw material medicament comprises the following aspects:
(1) essential oils are naturally attributed to health: the plant essential oil is a secondary metabolite in a plant body, consists of simple compounds with relatively small molecular weight, has a certain aromatic smell, can volatilize at normal temperature to form an oily liquid substance, and has biological activities of increasing aroma, sterilizing, resisting viruses, resisting oxidation and the like. The essential oil with the reputation of 'liquid gold' is accepted by more and more people by virtue of the advantages of being green, natural, safe, effective and the like;
(2) the formula is reasonable by taking the theoretical guidance of traditional Chinese medicine as a principle: through mutual synergistic administration of the angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil and the lavender essential oil, the effect is doubled, the traditional Chinese medicine is more suitable for diseases, and the treatment effect is better;
(3) safe and efficient: the essential oil is derived from herbs, is the concentrated essence of the effective components of plants, is more efficient, and has good transdermal property, faster effect and better effect.
The compound essential oil preparation for treating dysmenorrheal provided by the invention is based on the theory of traditional Chinese medicine, has a reasonable formula, selects different essential oils according to the principle of 'beard, class and inseparable', has strong fat solubility and permeability, is quickly absorbed by organisms, has the effects of pungent and fragrant smell flowing away, aromatic qi regulating, blood circulation promoting and pain relieving, has obvious pain relieving and menstruation regulating effects, can pass through external use, is safe, efficient, simple, convenient and quick, has higher patient acceptance and higher compliance by virtue of the synergistic cooperation of the angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil and the lavender essential oil.
In a preferred embodiment of the invention, the compound essential oil preparation for treating dysmenorrhea further comprises 90-98 parts by mass of base oil.
By adding the base oil into the compound essential oil preparation for treating dysmenorrhea, the essential oil composition has better skin-friendly property and can more quickly permeate into skin.
In the preferred embodiment of the present invention, the typical but non-limiting mass parts of the base oil in the compound essential oil preparation for treating dysmenorrhea are, for example, 90, 90.5, 91, 91.5, 92, 92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5 or 98 parts.
In a further preferred embodiment of the invention, the base oil is selected from at least one of sweet almond oil, jojoba oil, grape seed oil or wheat germ oil, preferably jojoba oil.
The sweet almond oil is neutral, not greasy, has good skin-friendly property and can moisten and soften the skin, so the sweet almond oil selected as the base oil has better effect.
In a preferred embodiment of the present invention, the angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil, the lavender essential oil, the geranium essential oil, the basil essential oil and the ginger essential oil are extracted from angelica sinensis, ligusticum wallichii, the cortex moutan, the rhizoma cyperi, the folium artemisiae argyi, lavender, geranium, basil and ginger respectively by a steam distillation method.
In another preferred embodiment of the present invention, the above essential oils can also be extracted by supercritical extraction.
The angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil, the lavender essential oil, the geranium essential oil, the basil essential oil and the ginger essential oil are prepared by a steam distillation method, so that the essential oils of various medicines are safer.
In a preferred embodiment of the invention, the compound essential oil preparation for treating dysmenorrhea further comprises pharmaceutically acceptable auxiliary materials.
The compound essential oil preparation for treating dysmenorrhea is added with pharmaceutically acceptable auxiliary materials, so that the preparation can be prepared into different dosage forms to meet the use requirements of patients.
In a further preferred embodiment of the invention, the auxiliary material comprises at least one of an excipient, a binder, a filler, a lubricant, an antioxidant or a thickener.
In a preferred embodiment of the invention, the essential oil agent for treating dysmenorrhea is an external preparation, and the compound essential oil agent for treating dysmenorrhea is set as the external preparation, so that the compound essential oil agent is safer and more convenient, and avoids side effects such as drug resistance, hepatotoxicity and the like caused by long-term administration.
In a preferred embodiment of the invention, the compound essential oil preparation for treating dysmenorrhea is an essential oil agent, a patch, a cream, a microemulsion gel or a suspension.
According to a second aspect of the present invention, the present invention provides a method for preparing a compound essential oil preparation for treating dysmenorrhea, comprising the following steps: mixing radix Angelicae sinensis essential oil, rhizoma Ligustici Chuanxiong essential oil, cortex moutan essential oil, rhizoma Cyperi essential oil, folium Artemisiae Argyi essential oil, Lavender essential oil, flos Pelargonii Hortori essential oil, herba Ocimi essential oil and rhizoma Zingiberis recens essential oil with optional base oil uniformly to obtain compound essential oil preparation for treating dysmenorrhea.
The preparation method of the compound essential oil preparation for treating dysmenorrhea, provided by the invention, is simple in process and convenient to operate, and can be suitable for industrial mass production and improve the production efficiency.
In a preferred embodiment of the present invention, when preparing the compound essential oil preparation for treating dysmenorrhea, angelica essential oil, ligusticum wallichii essential oil, cortex moutan essential oil, cyperus rotundus essential oil, artemisia argyi essential oil, lavender essential oil, geranium essential oil, basil essential oil and ginger essential oil are sequentially added to the base oil, and are uniformly mixed, such that the compound essential oil preparation for treating dysmenorrhea is prepared.
In a further preferred embodiment of the invention, the base oil is placed in a suitable container, the angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil, the lavender essential oil, the geranium essential oil, the basil essential oil and the ginger essential oil are sequentially added, the mixture is fully shaken uniformly to obtain the compound essential oil preparation for treating dysmenorrhea, and the compound essential oil preparation is stored in a sealed manner for later use.
According to a third aspect of the present invention, the present invention provides a method for using the essential oil composition for treating dysmenorrhea, comprising the following steps: applying the essential oil to the Guanyuan acupoint of the navel and the three-inch lower abdomen below the navel when female is dysmenorrhea or 3-7 days before menstrual period.
The compound essential oil preparation for treating dysmenorrhea is applied by external application, is safer and more convenient, and avoids the side effects of drug resistance, hepatotoxicity and the like caused by long-term oral administration of the medicine.
The technical solution provided by the present invention is further described below with reference to examples and comparative examples.
Example 1
The embodiment provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by mass: 1 part of angelica essential oil, 1.5 parts of ligusticum wallichii essential oil, 0.6 part of cortex moutan essential oil, 0.4 part of rhizoma cyperi essential oil, 0.7 part of folium artemisiae argyi essential oil, 0.8 part of lavender essential oil, 0.2 part of geranium essential oil, 0.5 part of basil essential oil, 0.3 part of ginger essential oil and 94 parts of jojoba oil, wherein the sum of the components is 100 parts.
Example 2
The embodiment provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by mass: 3 parts of angelica essential oil, 0.6 part of ligusticum wallichii essential oil, 0.4 part of cortex moutan essential oil, 0.25 part of rhizoma cyperi essential oil, 0.3 part of folium artemisiae argyi essential oil, 0.45 part of lavender essential oil, 0.4 part of geranium essential oil, 0.4 part of basil essential oil, 0.2 part of ginger essential oil and 94 parts of jojoba oil, wherein the sum of the components is 100 parts.
Example 3
The embodiment provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by mass: 1.5 parts of angelica essential oil, 1.2 parts of ligusticum wallichii essential oil, 0.4 part of cortex moutan essential oil, 0.4 part of rhizoma cyperi essential oil, 0.2 part of folium artemisiae argyi essential oil, 0.8 part of lavender essential oil, 0.4 part of geranium essential oil, 0.3 part of basil essential oil, 0.3 part of ginger essential oil and 94.5 parts of jojoba oil, wherein the sum of the components is 100 parts.
Example 4
The embodiment provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by mass: 2 parts of angelica essential oil, 1 part of ligusticum wallichii essential oil, 0.45 part of cortex moutan essential oil, 0.35 part of rhizoma cyperi essential oil, 0.3 part of folium artemisiae argyi essential oil, 0.5 part of lavender essential oil, 0.3 part of geranium essential oil, 0.3 part of basil essential oil, 0.4 part of ginger essential oil and 94.5 parts of jojoba oil, wherein the sum of the components is 100 parts.
Example 5
The embodiment provides a compound essential oil preparation for treating dysmenorrhea, which comprises the following components in parts by mass: 2.5 parts of angelica essential oil, 0.7 part of ligusticum wallichii essential oil, 0.5 part of cortex moutan essential oil, 0.3 part of rhizoma cyperi essential oil, 0.4 part of folium artemisiae argyi essential oil, 0.6 part of lavender essential oil, 0.35 part of geranium essential oil, 0.35 part of basil essential oil, 0.3 part of ginger essential oil and 94 parts of jojoba oil, wherein the sum of the components is 100 parts.
Example 6
The embodiment provides a preparation method of a compound essential oil preparation for treating dysmenorrhea, which comprises the following steps: placing jojoba oil in a suitable container, sequentially adding radix Angelicae sinensis essential oil, rhizoma Ligustici Chuanxiong essential oil, cortex moutan essential oil, rhizoma Cyperi essential oil, folium Artemisiae Argyi essential oil and Lavender essential oil, shaking thoroughly, and sealing for storage to obtain compound essential oil preparation for treating dysmenorrhea.
Comparative example 1
The comparative example provides an ibuprofen capsule.
Comparative example 2
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from the comparative example 5 in that geranium essential oil, basil essential oil and ginger essential oil are not added, and 95 parts of base oil is used.
Comparative example 3
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from the comparative example 5 in that no geranium essential oil is added, and 94.35 parts of base oil is added.
Comparative example 4
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from example 5 in that basil essential oil is not added, and 94.35 parts of base oil is used.
Comparative example 5
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from the comparative example 5 in that ginger essential oil is not added, and 94.3 parts of base oil is added.
Comparative example 6
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from the comparative example 5 in that geranium essential oil and basil essential oil are not added, and 94.7 parts of base oil is used.
Comparative example 7
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from the comparative example 5 in that no geranium essential oil and ginger essential oil are added, and 94.65 parts of base oil are used.
Comparative example 8
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, and is different from example 5 in that basil essential oil and ginger essential oil are not added, and 94.65 parts of base oil is used.
Comparative example 9
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, which comprises, by mass, 4 parts of angelica essential oil, 0.3 part of ligusticum wallichii essential oil, 0.2 part of cortex moutan essential oil, 0.2 part of rhizoma cyperi essential oil, 0.1 part of folium artemisiae argyi essential oil, 0.2 part of lavender essential oil, 0.8 part of geranium essential oil, 0.1 part of basil essential oil, 0.1 part of ginger essential oil and 94 parts of jojoba oil.
This comparative example differs from example 5 in the content of each essential oil component.
Comparative example 10
The comparative example provides a compound essential oil preparation for treating dysmenorrhea, which comprises, by mass, 0.5 part of angelica essential oil, 2 parts of ligusticum wallichii essential oil, 0.8 part of cortex moutan essential oil, 0.5 part of rhizoma cyperi essential oil, 0.1 part of folium artemisiae argyi essential oil, 1.1 part of lavender essential oil, 0.1 part of geranium essential oil, 0.1 part of basil essential oil, 0.8 part of ginger essential oil and 94 parts of jojoba oil.
This comparative example differs from example 5 in the content of each essential oil component.
Test example 1
A mouse clinical trial was performed for each example and comparative example to determine the effect of different groups on the treatment of dysmenorrhea.
1.1 materials
1.1.1 animals
Healthy adult female Wistar rats, clean grade, body mass 180-.
1.1.2 reagents and materials
Ibuprofen granules; rat serum IFN-kit; an IL-4ELISA kit; rat PGF2 enzyme-linked immunoassay kit; l-arginine methyl ester (L-NAME) and Rockwell's solution (Locke's solution-station);
1.1.3 instruments
A MacLab/4e four-channel physiological recorder;
1.2 mouse analgesia assay
1.2.1 establishment of pain model in mice by thermal stimulation at 55 ℃
The magnetic mouse is placed on a constant temperature hot plate instrument preheated to 55 ℃, the foot licking is taken as pain reaction, the latent period of the foot licking is taken as the pain threshold, and the average of the pain thresholds of the first 2 times of the drug is taken as the basic pain threshold.
1.2.2 determination of the Effect of the essential oil composition on pain threshold in mice
Selecting mice with qualified basal pain threshold values (pain threshold values are more than 5s and less than 30s) before administration, randomly dividing the mice into 16 groups, each group containing 10 mice, respectively preparing the medicaments for treating dysmenorrheal provided by the examples 1-5 and the comparative examples 1-10 into patches, then administering the medicaments for treating dysmenorrheal to the groups 1-15, wherein the groups 1-5 are administered with the compound essential oil (3.2g/kg) provided by the groups 1-5, the groups 6-15 are administered with ibuprofen granules (0.06g/kg) and the medicaments for treating dysmenorrheal provided by the groups 1-10, the group 16 is a blank control group, the same dose of distilled water is administered, and respectively recording the reactions of the mice in the 16 groups, and the results are shown in the following table 1:
TABLE 1 pain threshold in 22 groups of mice after dosing
Figure BDA0001761054790000131
Figure BDA0001761054790000141
As can be seen from the comparison between the groups 1-5 and 16 in Table 1, the compound essential oil preparations for treating dysmenorrhea provided by the examples 1-5 can significantly improve the threshold value of mice, which indicates that the compound essential oil preparation for treating dysmenorrhea provided by the invention has obvious analgesic effect.
As can be seen from the comparison between the 6 th and 16 th groups in table 1, the pain threshold of the ibuprofen group is not statistically significant compared to the blank control group.
As can be seen from comparison between 5 groups and 7-15 groups in table 1, the compound essential oil preparation for treating dysmenorrhea provided in example 5 has better analgesic effect on mice by synergistic combination of specific mass parts of angelica essential oil, ligusticum wallichii essential oil, cortex moutan essential oil, cyperus rotundus essential oil, artemisia argyi essential oil, lavender essential oil, geranium essential oil, basil essential oil and ginger essential oil.
1.3 rat analgesia assay
1.3.1 establishing rat dysmenorrhea model by oxytocin method
The influence of the drugs provided in examples 1-5 and comparative examples 1-16 on the activity of the uterine smooth muscle of rats is evaluated by using the contraction amplitude and frequency of the isolated uterine smooth muscle of the rat model of dysmenorrhea as indexes
1.3.2 Experimental methods
Female SD rats of the oxytocin-induced dysmenorrhea model were randomly divided into 16 groups of 10 animals each, each group was 1-16 groups, wherein the 16 th group was a blank control group, and except the 16 th group, the rats were injected with diethylstilbestrol 2mg/kg subcutaneously every day for 10 consecutive days. Starting on day 6 of the subcutaneous injection of diethylstilbestrol, 1 to 5 groups of patches of the compound essential oil preparations provided in examples 1 to 5 were administered, respectively, and 6 to 15 groups of patches made of the drugs provided in comparative examples 1 to 10 were administered, respectively. The same volume of distilled water was injected into 16 groups for 5 consecutive days. The oxytocin is injected into the abdominal cavity for 1 hour after the last administration, and the dosage is 20U/kg. The incubation period of the rats with pain response (writhing response) and the number of writhing within 30min were immediately recorded, and the inhibition rate of the number of writhing was calculated. The number of twists is the inhibition ratio (number of twists in model group-number of twists in administration group)/number of twists in model group × 100%. Rat serum PGF2αMeasuring the content of PGF2 in the serum of each group of rats 30min after injecting oxytocin, performing ether anesthesia, collecting blood from abdominal cavity vein, and measuringαThe content of (a). Meanwhile, after blood is taken from the model animal, the uterus of the rat is quickly taken out and placed in cold Rockwell fluid for cleaning, the middle section of the uterine horn at each side is taken to be 2cm and fixed in a constant temperature bath containing 10mL of Rockwell fluid on a tension transducer connected with MecLab/4 e. The temperature of nutrient solution in the bath is 37.5-38 ℃, and 95% O is introduced at constant rate2+5％CO2And (4) mixing the gases. Adjusting the trimmer, applying preload 1g, balancing for 40min, and recording contraction frequency and amplitude of animal uterus after spontaneous rhythm of uterus is recovered and contraction frequency and amplitude are stable。
TABLE 2 Effect of drugs on rat model
Figure BDA0001761054790000151
Figure BDA0001761054790000161
Note P < 0.05 compared to blank control; p < 0.01
As can be seen from the blanks of groups 1-5 and group 16 in Table 2, the compound essential oil preparations provided in examples 1-5 can significantly prolong the pain latency of rats and reduce the writhing frequency of rats, which indicates that the compound essential oil preparations provided in examples 1-5 have significant analgesic effect.
As can be seen from the comparison of groups 1-5 with 6, the analgesic effect of the compound essential oil formulations provided in examples 1-5 is comparable to that of ibuprofen granules.
As can be seen from comparison between groups 1-5 and groups 7-15, the compound essential oil preparation for treating dysmenorrhea provided in examples 1-5 has better analgesic effect on rats by synergistic combination of specific mass parts of angelica essential oil, ligusticum wallichii essential oil, cortex moutan essential oil, cyperus rotundus essential oil, artemisia argyi essential oil, lavender essential oil, geranium essential oil, basil essential oil and ginger essential oil.
TABLE 3 drug vs rat Ex vivo uterine contraction frequency and amplitude and PEG2 in serumαInfluence of (2)
Figure BDA0001761054790000162
Figure BDA0001761054790000171
As can be seen from Table 3, the uterine smooth muscle contraction frequency was significantly lower in the rats of groups 1-5 than in the 16 groups, PGF2αSignificantly lower than 16 groups, which shows that the compound essential oil preparation provided in examples 1-5 can significantly reduce the content of the essential oilRemarkably reduces the influence of oxytocin on the contraction of the uterine smooth muscle of rats and inhibits PEG2 in the ratsαCan be synthesized or released to reduce pain.
As can be seen by comparing groups 1-5 with 6, examples 1-5 provided essential oil compositions having slightly higher inhibitory effect on smooth muscle contraction than ibuprofen capsules.
As can be seen from comparison between groups 1-5 and groups 7-15, the compound essential oil preparation for treating dysmenorrhea provided in examples 1-5 has the effects of significantly reducing the effect of oxytocin on the contraction of rat uterine smooth muscle and inhibiting PEG2 in rat body through the synergistic cooperation of the angelica essential oil, the ligusticum wallichii essential oil, the cortex moutan essential oil, the rhizoma cyperi essential oil, the folium artemisiae argyi essential oil, the lavender essential oil, the geranium essential oil, the basil essential oil and the ginger essential oil in specific parts by massαCan be synthesized or released to reduce pain.
Test example 2
82 female patients with history of dysmenorrhea, age 17-38 years old, 45 experimental groups and 37 control groups were selected, and the experimental group and the control group had no obvious difference (P >0.05) in age, disease course and degree of dysmenorrhea and were comparable, wherein the experimental group was administered with the essential oil composition provided in example 5, the control group was administered with distilled water in equal amount, and the response index of the observed patients was measured and recorded, and the results are shown in tables 4-6.
TABLE 4 prostaglandin (PGF 2) menstrual blood before and after treatmentα) Comparison of levels (x. + -.s, pg/mL)
Example number (human) Before treatment After treatment
Experimental group (example 5) 45 465.4±51.76 351.2±53.42
Control group (distilled water) 37 472.7±51.4 430.81±35.24
As can be seen from the comparison between the experimental group and the control group in Table 4, the experimental group was able to significantly reduce PGF2 after the treatmentαThis shows that the essential oil composition provided by the experimental group has a therapeutic effect on dysmenorrhea of human bodies.
TABLE 5 comparison of the values of the blood sedimentation before and after treatment (mm/h)
Example number (human) Before treatment After treatment
Experimental group (example 5) 45 24.57±5.12 11.32±6.24
Control group (distilled water) 37 23.91±5.22 19.12±6.35
As can be seen from table 5, the essential oil composition provided in example 5 can increase blood perfusion, improve microcirculation, coordinate uterine functional activities, and relieve dysmenorrhea.
TABLE 6 clinical curative effect data sheet of patients (case%)
Figure BDA0001761054790000181
As can be seen from table 6, the total effective rate of the essential oil composition provided in example 5 in the user population reaches 95.6%, which indicates that the essential oil composition can regulate the prostate level in blood, thereby relieving the smooth muscle tension state, and can dredge and regulate blood, so that the uterine microcirculation state is effectively improved.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.

Claims (3)

1. The compound essential oil preparation for treating dysmenorrhea is characterized by comprising the following components in parts by mass: 2.5 parts of angelica essential oil, 0.7 part of ligusticum wallichii essential oil, 0.5 part of cortex moutan essential oil, 0.3 part of rhizoma cyperi essential oil, 0.4 part of folium artemisiae argyi essential oil, 0.6 part of lavender essential oil, 0.35 part of geranium essential oil, 0.35 part of basil essential oil, 0.3 part of ginger essential oil and 94 parts of jojoba oil, wherein the sum of the components is 100 parts;
the preparation method of the compound essential oil preparation for treating dysmenorrhea comprises the following steps: placing jojoba oil in a suitable container, sequentially adding radix Angelicae sinensis essential oil, rhizoma Ligustici Chuanxiong essential oil, cortex moutan essential oil, rhizoma Cyperi essential oil, folium Artemisiae Argyi essential oil and Lavender essential oil, shaking thoroughly, and sealing for storage to obtain compound essential oil preparation for treating dysmenorrhea;
wherein the essential oil of radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, cortex moutan, rhizoma Cyperi, folium Artemisiae Argyi, Lavender, flos Pelargonii Hortori, herba Ocimi and rhizoma Zingiberis recens is prepared by extracting radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, cortex moutan, rhizoma Cyperi, folium Artemisiae Argyi, Lavender, flos Pelargonii Hortori, herba Ocimi and rhizoma Zingiberis recens with steam distillation method.
2. The compound essential oil preparation for treating dysmenorrhea according to claim 1, wherein the preparation is in a form of an external preparation.
3. The compound essential oil preparation for treating dysmenorrhea according to claim 1, wherein the preparation is in the form of an essential oil agent, a patch, a cream, a microemulsion gel or a suspension.
CN201810907965.7A 2018-08-10 2018-08-10 Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof Active CN108815488B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810907965.7A CN108815488B (en) 2018-08-10 2018-08-10 Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810907965.7A CN108815488B (en) 2018-08-10 2018-08-10 Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof

Publications (2)

Publication Number Publication Date
CN108815488A CN108815488A (en) 2018-11-16
CN108815488B true CN108815488B (en) 2021-06-08

Family

ID=64152914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810907965.7A Active CN108815488B (en) 2018-08-10 2018-08-10 Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof

Country Status (1)

Country Link
CN (1) CN108815488B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109833411A (en) * 2019-03-15 2019-06-04 湖南逸红颜生物科技有限公司 A kind of rose essence oil and preparation method thereof for alleviating dysmenorrhea
CN112007137A (en) * 2020-09-14 2020-12-01 广东舒畅日用品有限公司 Compound essential oil with health care and conditioning effects and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1053363A (en) * 1990-09-11 1991-07-31 李竞 The perfume of energy prevention and relieving dysmenorrhea
CN103463263A (en) * 2013-09-10 2013-12-25 侯根香 Compound essential oil for relieving various pains
CN106267069A (en) * 2016-08-26 2017-01-04 欧芳生物科技（上海）股份有限公司 A kind of ovary warms up palace massage quintessence oil and preparation method thereof
CN107595947A (en) * 2017-02-17 2018-01-19 云南同方科技有限公司 A kind of plant essential oil composition and preparation method, application for being used to treat dysmenorrhoea
CN107693757A (en) * 2017-10-12 2018-02-16 广州番禺职业技术学院 It is a kind of that there is allotment essential oil for alleviating dysmenorrhoea effect and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1053363A (en) * 1990-09-11 1991-07-31 李竞 The perfume of energy prevention and relieving dysmenorrhea
CN103463263A (en) * 2013-09-10 2013-12-25 侯根香 Compound essential oil for relieving various pains
CN106267069A (en) * 2016-08-26 2017-01-04 欧芳生物科技（上海）股份有限公司 A kind of ovary warms up palace massage quintessence oil and preparation method thereof
CN107595947A (en) * 2017-02-17 2018-01-19 云南同方科技有限公司 A kind of plant essential oil composition and preparation method, application for being used to treat dysmenorrhoea
CN107693757A (en) * 2017-10-12 2018-02-16 广州番禺职业技术学院 It is a kind of that there is allotment essential oil for alleviating dysmenorrhoea effect and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
姚琰等.牡丹皮挥发油提取方法的研究.《中国药师》.2012,第15卷(第10期),第1411-1413页. *
牡丹皮挥发油提取方法的研究;姚琰等;《中国药师》;20121005;第15卷(第10期);第1141-1143页 *

Also Published As

Publication number Publication date
CN108815488A (en) 2018-11-16

Similar Documents

Publication Publication Date Title
CN1095610A (en) The pharmaceutical preparation Fubingkang of treatment, prevention gynecological diseases
CN103169928B (en) Externally applied traditional Chinese medicine composition for treating dysmenorrhea, as well as preparation method and application thereof
CN108815488B (en) Compound essential oil preparation for treating dysmenorrhea and preparation method and using method thereof
CN108714180B (en) Essential oil composition for treating dysmenorrhea, preparation method, preparation and using method
CN102145057A (en) Antispasmodic traditional Chinese medicine composition and preparation method thereof
CN102743703B (en) Medicament for treating cervical spondylosis and preparation method thereof
CN1695682A (en) External use preparation for treating rheumatisma and bone injuries
CN110354184A (en) The external drug and preparation method thereof for treating women cervical carcinoma
CN102872408A (en) Chinese medicinal preparation treating dysmenorrhea
CN101632756B (en) Traditional Chinese medicine for treating malignant tumours and preparation method thereof
CN113440500A (en) Plaster for treating dysmenorrhea and preparation method thereof
CN1895357A (en) Chinese medicine for treating kidney insufficiency
CN111904953A (en) Self-heating stroke acupoint application and preparation method thereof
CN108143759B (en) Pharmaceutical composition for relieving dysmenorrhea and preparation method thereof
CN101987135A (en) Medicine for treating tetanus and preparation method thereof
CN1251753C (en) Externally-applied medicine composition for treating mastoproliferation and its prepn
CN109833411A (en) A kind of rose essence oil and preparation method thereof for alleviating dysmenorrhea
CN111632087B (en) Five-vine medicinal liquor and preparation method and application thereof
CN1544019A (en) Chinese traditional medicine composition for treating arthralgia syndrome of cervical spondylopathy and its preparation
CN111481655B (en) External fumigation-washing traditional Chinese medicine composition for treating post-stroke myotonia increase
CN102526544B (en) Oral powder Chinese medicine formula for treating lumbar disc herniation and osteoproliferation
CN1091382C (en) Compound Lingxian headache-treating capsule and its preparation
CN116870072A (en) Traditional Chinese medicine composition, application, gel and preparation method of gel
CN104524025B (en) Traditional Chinese medicine composition for treating limb dysfunction after stroke
CN103505697A (en) Medicine used for treating orthopaedic diseases, and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant